Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde RLS Global

Related articles:
11/20/2023 12:49:01 PM - Tingsrätten försätter RLS Global i konkurs - Göteborgs tingsrätt har beslutat att bifalla forskningsbolaget RLS Globals konkursansökan och har försatt bolaget i konkurs. Det framgår av ett pressmeddelande.
11/20/2023 8:05:36 AM - RLS Global ansöker om konkurs - Styrelsen i forskningsbolaget RLS Global kommer idag ansöka om konkurs i Göteborgs tingsrätt, framgår det av ett pressmeddelande.
11/10/2023 10:08:47 AM - RLS Global: Terminated collaboration agreement with Convatec - Redeye - Redeye comments on yesterday’s news regarding RLS’ terminated collaboration agreement with Convatec. We argue that this development negatively impacts the company, introducing a level of uncertainty regarding its future. Due to the limited information available and the fact that RLS has initiated a review process, we opted to place our valuation and estimates under review. We will reassess our analysis once more information is available.
11/10/2023 6:25:51 AM - RLS Global avbryter samarbetet med Convatec - genomför strategisk granskningsprocess - Forskningsbolaget RLS Global och Convatec har beslutat att avbryta sitt samarbetsavtal rörande ChloraSolv på de europeiska marknaderna. De kommersiella rättigheterna till ChloraSolv kommer även att återlämnas till RLS Global.
8/28/2023 5:36:03 AM - RLS Global Q2 2023: Uncertain future - Redeye - Redeye provides an update in relation to RLS’ Q2 2023 report. The report did not include any major surprises in our view, with low sales and OPEX similar to previous quarters; however, the information provided by the company is still limited, creating concerns of the future. Due to the company’s future uncertainties, we have chosen to decrease our sales expectations, which renders an updated fair value range, including a new base case of SEK5.5 (7).
6/1/2023 5:13:47 AM - RLS Global Q1 2023: Delay in Europe but progress in the Middle East - Redeye - Redeye provides an update in relation to RLS’ Q1 2023 report. The report did not include any major surprises in our view, with low sales and OPEX similar to previous quarters; however, we got mixed feelings from the CEO message regarding the launch of ChloraSolv. In relation to the report, we have chosen to only make some minor changes in our sales estimates for 2023e and adjust our capital-raising assumptions. The changes results in an updated fair value range.
3/1/2023 7:31:57 AM - RLS Global Q4 2022: No surprises – but expectations of an eventful 2023 - Redeye - Redeye provides an update in relation to RLS’ Q4 2022 report. The report did not include any major surprises in our view; however, we expect quarterly reports to become more interesting as we expect sales to ramp up during 2023. We make some changes in our OPEX assumptions, include a future capital raising, and increase the WACC to 13.5% (12.5%) because of an updated Redeye Rating. The changes result in a new fair value range.
3/1/2023 7:14:20 AM - RLS Global Q4 2022: No surprises – but expectations of an eventful 2023 - Redeye - Redeye provides an update in relation to RLS’ Q4 2022 report. The report did not include any major surprises in our view; however, we expect quarterly reports to become more interesting as we expect sales to ramp up during 2023. We make some changes in our OPEX assumptions, include a future capital raising, and increase the WACC to 13.5% (12.5%) because of an updated Redeye Rating. The changes result in a new fair value range.
11/24/2022 11:28:49 AM - RLS Global: Our comments - Redeye - Redeye comments on RLS Global´s Q3 2022 report. The report did not include any surprises, in our view. We do not expect sales to ramp up until 2023e; therefore, we make some changes in our estimates, leading to an updated base case from SEK10 to SEK9.
11/15/2022 10:29:29 AM - RLS Global: Rights issue outcome - Redeye - Redeye comments on RLS Global’s rights issue outcome. The subscription breakdown shows that c.70% was subscribed, and underwriters to the rights issue will be allocated c.30% of the issue. As the issue was fully guaranteed, we have already adjusted our fair value range in our previous note. We reiterate our base case of SEK10.
10/20/2022 9:13:54 AM - RLS Global: Rights Issue Announcement - Redeye - Redeye comments on RLS Global’s rights issue announcement. The issue is fully guaranteed and will provide RLS with approximately SEK29.4m before issue costs. We adjust our fair value range accordingly to the news, leading to a new diluted Base Case from SEK12 to SEK10.
9/23/2022 10:26:21 AM - RLS Global: Directed Issue - Redeye - Redeye comments on RLS’s directed issue of new shares to Zebra holdings and Investments Limited. The purpose of the issue is to pay the remaining debt to Zebra of SEK 10m. We adjust our model accordingly to the news; however, our fair value remains mostly the same with a Base Case of SEK 12, and Bull and Bear Case of SEK 17 and SEK 3(4), respectively.
8/26/2022 10:10:58 AM - RLS Global Q2: Our comments - Redeye - Redeye comments on RLS Global’s Q2’22 report. The report did not have any surprises, and half-year sales reached SEK 0.7m (SEK 0.3m). We believe the company will soon enter an exciting phase. As the collaboration with ConvaTec and geographical expansion continue, we hope to start seeing more sales activities during the rest of 2022.
7/13/2022 8:31:14 AM - RLS Global: ChloraSolv is now Available in the UK - Redeye - Redeye endorses that ChloraSolv now is available in the UK through NHS Supply Chain. We expected the approval and are positive about the geographical expansion that we believe will continue during the rest of the year. We reiterate our Base Case of SEK 12.
6/1/2022 8:52:44 AM - RLS Global: Entering the Veterinary Care Segment - Redeye - Redeye endorses RLS introducing ChloraSolv in the veterinary care segment in Scandinavia by entering a strategic partnership with the animal care wholesaler, Swevet.
5/30/2022 9:09:10 AM - RLS Global: Progressing in the Middle East - Redeye - Redeye is encouraged to learn that RLS is strengthening its presence in the Middle East by establishing a local distribution network in Egypt, Saudi Arabia, Iraq, Lebanon, Qatar, the United Arab Emirates, Oman and Jordan through a regional agent.
5/11/2022 9:56:08 AM - RLS Global: Our Q1’22 Comment - Redeye - Redeye provides its comments on RLS’ Q1’22 report. With reimbursement in place in the Netherlands as well as ongoing discussions in other European countries, we expect the sales ramp-up to start taking off in the coming quarters.
4/4/2022 12:05:11 PM - RLS Global: Unexpected CEO Announcement - Redeye - Redeye provides a short comment on today’s news regarding CEO Karin Fischer’s decision to leave.
2/25/2022 10:16:43 AM - RLS Global Q4’21: Progressing According to Plan - Redeye - Redeye provides its comments on RLS’s Q4’21 report. With an imminent European launch of ChloraSolv together with ConvaTec, 2022 will likely be RLS’s most interesting year so far. We reiterate our Base Case.
1/12/2022 10:08:45 AM - RLS Global: Progressing in the Netherlands - Redeye - Redeye is encouraged to learn that RLS has made progress in the Netherlands. ChloraSolv is now listed on the Z-Index and will thus be fully reimbursed by the National Health Care Institute (Zorginstituut Nederland). We continue to argue that RLS has an exciting year ahead and that the share is very attractive at current share price levels.
11/19/2021 10:27:51 AM - RLS Global: Initial Order From ConvaTec and Funding Secured - Redeye - Redeye is encouraged to learn that RLS has secured a credit facility of SEK 20m as well as received its first order from ConvaTec. With an improved financial flexibility, while the collaboration with ConvaTec is now entering a more active commercialization phase, we believe that the investor sentiment will improve over the coming months. We continue to argue that the stock offers an attractive risk/reward at current share price levels.
11/12/2021 2:27:22 PM - RLS Global Q3’21: Commercial Launch Approaching - Redeye - Redeye maintains its optimistic view on RLS following today’s Q3 report and continues to argue that the stock offers an attractive risk/reward at current share price levels.
10/15/2021 11:13:59 AM - RLS Global: Key Takeaways From the Strategy Update - Redeye - Redeye provides some key takeaways from RLS Global’s Strategy Update held on October 14. The presentation focused on the long-term vision based on the company’s platform, the global partnership with ConvaTec as well as key objectives over the coming years.
10/13/2021 1:59:02 PM - RLS Global: Bolagspresentation på Naventus Life Science Summit - RLS Global presenterar på Naventus Life Science Summit som ägde rum 29:e september 2021.
9/28/2021 11:59:53 AM - Naventus Life Science Summit - Onsdag den 29:e september kl.09:00 är det dags för Naventus Life Science Summit.
8/30/2021 11:08:49 AM - RLS Global: Regulatory Approval in New Zeeland - Redeye - Redeye comments on the regulatory approval in New Zeeland and maintains its positive view of RLS. The share is currently trading far below our Base Case.
7/16/2021 3:31:32 PM - RLS Global: Q2, Entering an Interesting Period - Redeye - Redeye maintains its optimistic view of RLS following today’s Q2 report and still believes that the first order under the global distribution agreement with ConvaTec, which we expect to take place during the autumn, will act as a key catalyst for the stock.
6/30/2021 12:27:27 PM - RLS Global: Partner Validation - Redeye - Redeye updates its RLS case following the company’s global distribution agreement with ConvaTec. With this deal validating the huge potential in RLS’s proprietary platform, we increase our fair value range and see upside potential of some 75% to our Base Case.
6/17/2021 1:00:02 PM - RLS Global: A Deal That Validates the Platform Potential - Redeye - Redeye provides a first comment on the deal with ConvaTec. In our view, the deal represents a clear validation of ChloraSolv and the huge potential in RLS' buffered hypochlorite platform. We intend to get back with a longer research note soon.
5/7/2021 3:03:37 PM - RLS Global Q1: Comments on the report - Redeye - Redeye comments on the Q1 report. In short, sales have been heavily affected by the pandemic though there are hopes that its operations will return to a higher degree during and after the summer. Moreover, a potential signing with a partner is still an active catalyst for the case.
4/29/2021 12:40:06 PM - RLS Global: Leg ulcers indication approved - Redeye - Redeye welcomes the regulatory approval of the indication of leg ulcers for ChloraSolv, adding significant market potential for the company. The approval is an important event for the case and further strengthens our thesis, though not impacting our Base Case as such – we had already included it in our forecasts and valuation, which at current levels suggests an attractive upside.
10/15/2019 10:57:16 AM - Stena och Lundinfamiljen ökade i RLS Globals riktade nyemission - Stena och Lundinfamiljen ökade i RLS Globals riktade nyemission
9/26/2019 6:51:37 AM - RLS Global tar in 50 miljoner kronor i riktad nyemission - RLS Global tar in 50 miljoner kronor i riktad nyemission